• FDA Approves Octapharma’s Octagam 10% for Adult Dermatomyositis drugs
    July 23, 2021
    FDA has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.
PharmaSources Customer Service